Thyroid nodules represent a highly prevalent clinical challenge, with detection rates reaching 65-70% in the general population when evaluated by high-frequency ultrasound (1, 2). Although more than 90% of these nodules are benign, a subset requires intervention due to compressive symptoms, cosmetic concerns, or patient anxiety regarding potential malignant transformation (2). The increasing detection of symptomatic benign thyroid nodules has driven demand for effective treatment strategies that balance therapeutic efficacy with preservation of thyroid function and patient quality of life.

Traditional surgical thyroidectomy, while definitive, carries significant morbidity including a 2.10% rebleeding rate, 0.97% nerve paresis, and 4.40% hypocalcemia at 6 months post-operatively, along with inevitable scarring and the potential need for lifelong hormone replacement therapy (3, 4). These limitations have catalyzed the development of minimally invasive ablation techniques, progressing from percutaneous ethanol injection to thermal ablation methods including laser ablation, radiofrequency ablation (RFA), and most recently, microwave ablation (MWA) (5). MWA offers distinct technical advantages including reduced treatment time, larger ablation zones, and decreased heat sink effect, making it particularly suitable for highly vascular thyroid tissue (3, 5).

Despite these theoretical advantages, clinical outcomes remain heterogeneous with concerning variability in treatment success. Recent multicenter studies report volume reduction ratios (VRR) ranging from 73% to 81% at 12–24 months, while complete nodule disappearance rates vary dramatically from 15.2% to 97.6% (4, 6). This substantial variability suggests that current “one-size-fits-all” energy delivery protocols fail to account for critical patient-specific factors. The mean energy requirement per volume reduction ranges from 0.4 to 4.6 kJ/ml, with solid nodules requiring 2.30 ± 1.5 kJ/ml compared to only 0.75 ± 0.25 kJ/ml for cystic nodules, highlighting the need for individualized energy planning (7).

The biophysical principles underlying successful ablation depend on achieving temperatures of 60-100 °C throughout the target volume while avoiding carbonization, which occurs above 105 °C and is associated with increased complications and treatment insufficient (8). Multivariate analyses have identified nodule composition, enhancement patterns, and baseline volume as independent factors affecting ablation efficacy, yet these insights have not been systematically integrated into clinical protocols (5). Furthermore, nodule location relative to critical structures, vascularity assessed by contrast-enhanced ultrasound, and patient-specific metabolic factors all influence heat distribution and ablation completeness (9).

Therefore, this study aims identifying key predictors of treatment success in microwave ablation for benign thyroid nodules, developing and validate a multivariable model for optimal energy density calculation incorporating morphological, functional, and patient-specific parameters; and establishing a clinically applicable algorithm for personalized energy delivery.

This study establishes a comprehensive predictive framework for microwave ablation outcomes in benign thyroid nodules, developing the first multi-parametric energy density optimization algorithm. Our study achieved a mean volume reduction ratio (VRR) of 83.6 ± 12.0% at 12 months, which is comparable to recent multicenter studies reporting mean VRR of 70.8% at median 109-day follow-up (10) and 76% at 12 months following standardized protocols (11). However, when applying a stringent success criterion (VRR >90%), only 37.8% of patients achieved this threshold, highlighting the need for optimized energy delivery protocols. This discrepancy underscores fundamental limitations in current one-size-fits-all approaches. Our finding that baseline volume demonstrated strong negative correlation (r = -0.27) with treatment success aligns with recent evidence that smaller nodules achieve superior outcomes, with volume reduction significantly greater in nodules <30mL versus >30mL (P = 0.0266) (12). The development of individualized energy delivery protocols represents a critical advance, particularly given evidence that solid nodules require substantially higher energy density than cystic components (13).

The plateau effect observed above 4.0 J/mm³ provides crucial mechanistic insights into thermal ablation limitations. Recent studies demonstrate that excessive energy delivery fails to improve outcomes, with total energy ranging from 1477-7206J showing similar efficacy patterns (14). This phenomenon likely reflects tissue carbonization and heat sink effects that limit further energy deposition effectiveness. A recent RATED study analyzing learning curves found stable treatment efficacy achieved after 20 procedures with median VRR of 70.8%, but notably, neither baseline volume nor energy delivered predicted treatment success beyond initial experience (15). Our data showing energy density >2.19 J/mm³ improved outcomes aligns with reports that monopolar RFA systems require careful energy titration to avoid complications while achieving adequate ablation zones (16). The observation that excessive energy provides diminishing returns challenges current practices and supports precision-based approaches targeting optimal rather than maximal energy deposition.

Five independent predictors emerged from our multivariable analysis, explaining 52% of variance in optimal energy density. The inverse relationship with vertical diameter (β = -6.44, P < 0.001) suggests smaller vertical dimensions require concentrated energy for complete ablation, consistent with geometric modeling showing cylindrical ablation fields of approximately 2cm diameter (17). Baseline volume’s positive correlation (β = 0.007, P = 0.001) reflects proportional energy requirements, supported by machine learning models identifying initial volume as the strongest predictor (18). TSH level’s emergence as a significant predictor (β = 13.75, P = 0.044) represents a novel finding potentially reflecting metabolic activity influencing tissue perfusion and heat dissipation. The neutrophil count association (β = 0.44, P = 0.009) suggests baseline inflammatory status affects thermal conductivity, paralleling observations in other thermal ablation contexts (19).

CEUS enhancement patterns demonstrated remarkable predictive value, with hypo-enhancement achieving 41.9% success rate versus 13.7% in failures (P = 0.004). These finding parallels recent validation studies showing hypo-enhancement predicts favorable ablation outcomes through reduced perfusion-mediated heat dissipation (20). Iso-enhancement showed markedly reduced success odds (OR = 0.06, 95% CI: 0.01-0.41), suggesting enhanced vascularity compromises thermal coagulation through increased heat sink effects. Peak intensity’s negative correlation (β = -3.22, P = 0.037) further supports vascular perfusion as a critical determinant of ablation efficacy. These findings align with consensus guidelines recommending CEUS for pre-procedural planning and post-ablation assessment (21).

Inflammatory markers showed unexpected associations with treatment outcomes. Elevated CRP (OR = 1.38, 95% CI: 1.09-1.73, P = 0.007) independently predicted success, contrasting with cardiac ablation literature where higher CRP predicts recurrence (22). Reduced WBC count (OR = 0.54, 95% CI: 0.31-0.93, P = 0.028) similarly predicted favorable outcomes. These paradoxical findings suggest tissue-specific inflammatory responses in thyroid versus other organs, potentially reflecting underlying nodule characteristics affecting both baseline inflammation and thermal susceptibility. The lymphocyte count trend (P = 0.111) warrants further investigation given emerging evidence linking immune responses to ablation outcomes.

Our three-step personalized algorithm addresses critical gaps in current practice. Step 1 calculates baseline energy density incorporating morphological and biochemical parameters. Step 2 estimates success probability using logistic regression with excellent discrimination (AUC = 0.902). Step 3 implements adaptive adjustment, increasing energy density proportionally when predicted success falls below 80%. This approach optimizes treatment planning while avoiding overtreatment in favorable cases. Recent artificial intelligence models achieving similar predictive performance validate the feasibility of algorithmic treatment planning (23). The algorithm’s clinical utility extends beyond individual treatment optimization, potentially stratifying patients for alternative therapies when success probability remains low despite energy adjustment.

Several limitations warrant consideration. The retrospective single-center design limits generalizability, particularly given operator experience influences outcomes as demonstrated in learning curve analyses (23). Sample size of 82 patients, while adequate for model development, requires external validation in larger multicenter cohorts. Absence of operator experience quantification represents a significant unmeasured confounder, given evidence that procedural volume affects outcomes. The 12-month follow-up, while standard, may miss late recurrences occurring at 3+ years post-ablation. Additionally, our stringent success definition (>90% VRR) exceeds typical clinical thresholds, potentially underestimating clinical effectiveness.

In conclusion, this study demonstrates that individualized energy density calculation has the potential to significantly enhance microwave ablation outcomes for benign thyroid nodules. The integration of morphological, biochemical, and vascular parameters into a comprehensive predictive algorithm represents a paradigm shift from standardized to personalized ablation protocols. Prospective multicenter validation studies are warranted to confirm the clinical efficacy of this algorithm and explore additional predictive biomarkers and long-term outcomes beyond 12 months.